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Generic Duragesic (Fentanyl) Patches  
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Background 
On January 28, 2005 Mylan Technologies 
received FDA approval of the abbreviated new 
drug application (ANDA) for their Fentanyl 
Transdermal Systems products.  Approved were 
the 25 mcg/hour, 50 mcg/hour, 75 mcg/hour, and 
100 mcg/hour products.  The FDA deemed these 
products bioequivalent and therapeutically 
equivalent to the reference drug, Duragesic 
Transdermal Systems.1 
Duragesic is manufactured by Alza 
Corporation and distributed by Janssen 
Pharmaceutica Products.  Alza is also 
manufacturing a generic fentanyl patch which is 
identical to Duragesic but is distributed by 
Sandoz and bears the Sandoz generic labeling.  It 
is bioequivalent and therapeutically equivalent to 
Duragesic since it is the same product.   
An evaluation of therapeutic equivalence is 
assigned to pharmaceutical equivalents only if the 
approved application contains adequate scientific 
evidence, established through in vivo and/or in 
vitro studies, that there is bioequivalence of the 
product to a selected reference product.2 
Currently, these two generic fentanyl patches 
are the only FDA approved products but others 
are under FDA review.  Lavipharm Corp and 
Endo Pharmaceuticals Inc. have submitted 
abbreviated new drug applications to the FDA. 
 
Product Differences and Similarities 
Mylan’s fentanyl transdermal system differs 
from the Alza-produced Duragesic and Sandoz 
generic patches.  Mylan patches are smaller in 
size compared with the equivalent Duragesic or 
Sandoz products.  The primary difference is the 
drug reservoir.3,4  
Mylan uses a solid matrix fentanyl-containing 
silicone adhesive that is sandwiched between a 
backing film and protective liner.  Just prior to use 
the protective liner is removed and the rate-
controlling fentanyl matrix is applied to the skin.4   
Duragesic and the Sandoz generic have a 
liquid fentanyl reservoir.  The system consists of 
an external backing layer, the reservoir of fentanyl 
and alcohol USP gelled with hydroxyethyl 
cellulose, an ethylene-vinyl acetate copolymer 
membrane, a fentanyl-containing silicone 
adhesive, and a protective liner.  This liner is 
removed prior to application.  In this system the 
ethylene-vinyl copolymer membrane controls the 
drug delivery rate.3   
Janssen distributes the only 12.5 mcg/hour 
product.  There are no currently available generic 
equivalents for this product.  It was approved by 
the FDA in February 2005.   
All generic products have the same prescribing 
information as Duragesic in their labels.3,4 
All used patches contain residual fentanyl in 
their matrices and should be folded so that the 
adhesive sides adhere to each other.3,4  All generic 
products create the same diversion potential as the 
brand name.5 
Based on the average wholesale drug cost, the 
generic fentanyl patches cost approximately six 
percent less than Duragesic patches.6 
 
Commentary 
With the availability of generic fentanyl 
patches, formulary-driven insurance plans and 
group buying contract decisions may necessitate 
conversion from the Duragesic patch to a generic 
patch.  Because of the FDA AB rating, patch 
conversion concerns should be minimized.1   
There have been reports posted on the 
American Pain Foundation’s website describing 
differences in analgesic efficacy and side effects.7  
Concerns mentioned in postings to their 
discussion board state that both the Mylan and 
Sandoz generics are not as effective.  Some 
postings also describe that there are more side 
effects such as nausea and vomiting with the 
generic versions.7  
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Issues of efficacy may be perceived due to the 
smaller size of the Mylan patches as compared to 
the Duragesic patches and also the fact that they 
are generics.  Some believe that generics don’t 
work as well as the brand name product.    Post-
marketing investigation of reports may reveal 
actual differences.  An individual’s perception of 
pain and pain-relief is subjective and must be 
evaluated with reference to the person’s pain 
control goal.  Encourage reporting of product 
problems.  To report product problems, call the 
FDA MEDWATCH program at 1-800-FDA-1088. 
The MEDWATCH program is also available on-
line at www.fda.gov/medwatch.  Or report to the 
USP Medication Errors Reporting Program in 
cooperation with the Institute for Safe Medication 
Practices at 1-800-23-ERROR or at 
www.usp.org/patientSafety/reporting/mer.html.   
Be aware of the potential for actual or 
perceived differences when switching fentanyl 
patch products.  Patients who have always used 
the Duragesic patch may need to be monitored 
more closely when switching to a generic patch.  
During the conversion to a generic patch some 




Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input 
from experts, government agencies, and national 
organizations.  Information and Internet links in this 
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